Clinical Trial Update: Phase IIb Study of PRO045 in Subjects With Duchenne Muscular Dystrophy [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 study of PRO045 in Duchenne muscular dystrophy has been terminated. The termination status is indicated in the trial update.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Duchenne Muscular Dystrophy

Drugs mentioned

• PRO045

Snippet

Sponsor: BioMarin Pharmaceutical | Conditions: Duchenne Muscular Dystrophy | Phase 1, Phase 2 | Status: TERMINATED